Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease (SCD). The company is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700
Debt
Debt-to-Equity RatioN/A
Current Ratio23.12
Quick Ratio23.12
Price-To-Earnings
Trailing P/E Ratio-15.24
Forward P/E Ratio-11.62
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.93 per share
Price / Book6.07
Profitability
EPS (Most Recent Fiscal Year)($2.76)
Net Income$-117,020,000.00
Net MarginsN/A
Return on Equity-38.74%
Return on Assets-35.69%
Miscellaneous
Employees147
Outstanding Shares51,830,000
Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions
What is Global Blood Therapeutics' stock symbol?
Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."
How were Global Blood Therapeutics' earnings last quarter?
Global Blood Therapeutics Inc (NASDAQ:GBT) announced its earnings results on Monday, May, 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.91) by $0.04. During the same quarter last year, the firm posted ($0.60) EPS. View Global Blood Therapeutics' Earnings History.
When is Global Blood Therapeutics' next earnings date?
What price target have analysts set for GBT?
12 Wall Street analysts have issued 12 month price targets for Global Blood Therapeutics' shares. Their forecasts range from $46.00 to $91.00. On average, they anticipate Global Blood Therapeutics' share price to reach $72.4167 in the next twelve months. View Analyst Ratings for Global Blood Therapeutics.
What are Wall Street analysts saying about Global Blood Therapeutics stock?
Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
- 1. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (5/2/2018)
- 2. Needham & Company LLC analysts commented, "Here we review our expectations for Part A of the HOPE trial which includes survey findings from 36 sickle cell disease (SCD) experts. We believe there is more than one path forward for voxelotor, but we think upside potential could vary significantly based on Part A findings. If reported Part A outcomes meet expectations as defined below, we think the stock could easily return to the $70 level (+60%) it was trading at in January." (4/26/2018)
- 3. Cantor Fitzgerald analysts commented, "At ASH, Global Blood announced multi-dose Phase 2a data with voxelotor (GBT440), in adolescent (ages 12-17) patients." (12/11/2017)
- 4. Cowen Inc analysts commented, "GBT reported Q3 earnings last week and provided a brief summary of their progress." (11/9/2017)
Who are some of Global Blood Therapeutics' key competitors?
Some companies that are related to Global Blood Therapeutics include SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY) and Ultragenyx Pharmaceutical (RARE).
Who are Global Blood Therapeutics' key executives?
Global Blood Therapeutics' management team includes the folowing people:
- Dr. Ted W. Love, Pres, CEO & Director (Age 59)
- Dr. Charles J. Homcy, Founder, Advisor & Director (Age 70)
- Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 56)
- Ms. Tricia Borga Suvari Esq., Chief Legal Officer and Sec. (Age 57)
- Dr. David R. Phillips Ph.D., Founder and Advisor
When did Global Blood Therapeutics IPO?
(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.
Has Global Blood Therapeutics been receiving favorable news coverage?
Media coverage about GBT stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Global Blood Therapeutics earned a news sentiment score of 0.08 on Accern's scale. They also assigned media stories about the company an impact score of 47.97 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Global Blood Therapeutics' major shareholders?
Global Blood Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.26%), Franklin Resources Inc. (1.20%), Northern Trust Corp (0.93%), Fernwood Investment Management LLC (0.69%), Nexthera Capital LP (0.61%) and Loomis Sayles & Co. L P (0.57%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Lesley Ann Calhoun, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.
Which major investors are selling Global Blood Therapeutics stock?
GBT stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., BlackRock Inc., JPMorgan Chase & Co., Loomis Sayles & Co. L P, Candriam Luxembourg S.C.A., GW&K Investment Management LLC, Eversept Partners LLC and Iguana Healthcare Management LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Charles J Homcy, Deval L Patrick, Jung Choi, Lesley Ann Calhoun and Peter Radovich. View Insider Buying and Selling for Global Blood Therapeutics.
Which major investors are buying Global Blood Therapeutics stock?
GBT stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Frontier Capital Management Co. LLC, Columbus Circle Investors, BNP Paribas Arbitrage SA, Royal Bank of Canada, UBS Group AG, Spark Investment Management LLC and Northern Trust Corp. View Insider Buying and Selling for Global Blood Therapeutics.
How do I buy shares of Global Blood Therapeutics?
Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Global Blood Therapeutics' stock price today?
One share of GBT stock can currently be purchased for approximately $42.05.
How big of a company is Global Blood Therapeutics?
Global Blood Therapeutics has a market capitalization of $2.14 billion. The company earns $-117,020,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Global Blood Therapeutics employs 147 workers across the globe.
How can I contact Global Blood Therapeutics?
Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]
MarketBeat Community Rating for Global Blood Therapeutics (GBT)
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
